Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-…

Inflammatory cytokine interleukin (IL)-6 is elevated in the serum and lungs of patients with
pulmonary artery hypertension (PAH). Several animal models of PAH cite the potential role of …

Background Some patients with COVID-19 who have recovered from the acute infection
after experiencing only mild symptoms continue to exhibit persistent exertional limitation that …

Background Mitochondrial DNA (mtDNA) is a critical activator of inflammation and the innate
immune system. However, mtDNA level has not been tested for its role as a biomarker in …

Background— The clinical relevance of exercise-induced pulmonary arterial hypertension (PAH)
is uncertain, and its existence has never been well studied by direct measurements of …

Dysregulation of vascular stiffness and cellular metabolism occurs early in pulmonary
hypertension (PH). However, the mechanisms by which biophysical properties of the vascular …

Background— Pulmonary hypertension (PH) is driven by diverse pathogenic etiologies. Owing
to their pleiotropic actions, microRNA molecules are potential candidates for coordinated …

Development of the vascular disease pulmonary hypertension (PH) involves disparate
molecular pathways that span multiple cell types. MicroRNAs (miRNAs) may coordinately …

Pulmonary hypertension (PH) is a deadly vascular disease with enigmatic molecular origins.
We found that vascular extracellular matrix (ECM) remodeling and stiffening are early and …

Hyperoxic lung injury is commonly encountered in patients who require treatment with high
concentrations of inspired oxygen. To determine whether interleukin (IL)-6 is protective in …